Is Omega-3 Good for a Fatty Liver?

Omega-3 fatty acids can reduce the amount of fat stored in the liver, according to several pooled analyses of clinical trials. But the benefit is narrower than supplement marketing tends to suggest. While liver fat itself appears to drop with omega-3 supplementation, the evidence for reversing inflammation, scarring, or the more advanced stages of fatty liver disease is weaker and, in some recent analyses, absent. The picture is also shifting: a 2025 meta-analysis using the most precise imaging methods found no significant effect on liver fat at all, raising questions about how robust the earlier positive findings really are.

What Pooled Trials Have Found

The case for omega-3 and fatty liver rests largely on meta-analyses, which combine results from multiple smaller trials to get a clearer signal. A 2011 systematic review published in the Journal of Hepatology pooled data from both randomized and non-randomized studies and found a significant reduction in liver fat favoring omega-3 supplementation, with the benefit holding up when the analysis was restricted to randomized controlled trials alone.¹ A later meta-analysis in Gastroenterology Research and Practice confirmed that omega-3 improved liver fat content and also improved blood triglycerides, HDL cholesterol, and levels of the liver enzyme GGT, though it did not significantly change other common liver enzymes like ALT and AST.²

These results were encouraging, but they came with caveats the authors themselves noted: the optimal dose was unknown, the studies were generally small, and most used ultrasound to measure liver fat, which is less precise than newer imaging techniques. That matters, because a 2025 meta-analysis that specifically looked at trials using magnetic resonance spectroscopy or MRI-based fat fraction measurements found no significant effect of omega-3 on liver fat, liver stiffness, liver enzymes (ALT and AST), or histology.³ In other words, when researchers used more accurate tools and looked at a broader set of trials, the liver-fat-reduction signal faded. This does not mean omega-3 does nothing for a fatty liver, but it does mean the early enthusiasm may have been inflated by less precise measurement methods and small sample sizes.

The Fibrosis and Inflammation Gap

Fatty liver disease is not just about fat. The reason doctors worry about it is that accumulated fat can trigger inflammation, and chronic inflammation can lead to scarring (fibrosis), which in its advanced form is cirrhosis. For omega-3 to be truly useful against fatty liver disease, it would ideally do more than just reduce fat; it would also need to slow or reverse the inflammatory and fibrotic damage.

On this front, the evidence is disappointing. A meta-analysis of randomized trials in PLOS ONE found that omega-3 supplementation lowered ALT levels, but the effects on AST and GGT did not reach statistical significance. Of the three trials in that analysis that examined fibrosis specifically, only one reported any improvement.⁴ A double-blind, placebo-controlled trial published in the Journal of Hepatology tested omega-3 against placebo in patients with confirmed NASH, the more severe inflammatory form of fatty liver. Omega-3 did not significantly outperform placebo on the primary endpoint, which was a meaningful reduction in the NASH activity score without fibrosis getting worse. What it did do was reduce liver fat on imaging, especially in patients whose weight stayed the same or increased, suggesting it can counteract some fat accumulation independent of weight loss.⁵

The pattern across the literature is consistent: omega-3 may reduce the amount of fat in the liver, but it has not been shown to reliably improve the inflammatory or scarring component of the disease. If you already have NASH (now increasingly called MASH under newer terminology), omega-3 supplements alone are unlikely to reverse the histological damage.

How Omega-3 Affects the Liver at a Cellular Level

The liver is constantly balancing two processes: making new fat (lipogenesis) and burning fat for energy (oxidation). Omega-3 fatty acids appear to shift this balance toward burning. In animal studies, supplementation with long-chain omega-3s changed the ratio of two key regulatory signals in liver cells, pushing the liver away from a fat-building state and toward one that favors fat breakdown.⁶ A proteomic study of liver tissue from patients with NASH found that omega-3 supplementation altered markers related to fat production, cellular stress, and energy pathways in ways that pointed toward less fat toxicity and more efficient mitochondrial fat burning.⁷

Separate work using mice engineered to produce their own omega-3s showed that their liver mitochondria consumed more oxygen, burned more fatty acids, and generated energy substrates more efficiently than those of normal mice on the same diet.⁸ Together, these findings suggest that omega-3 does not just passively displace liver fat; it actively changes how liver cells process fuel. The disconnect between these promising mechanistic findings and the modest clinical results likely reflects the difference between controlled lab conditions and the messiness of human disease, diet, genetics, and compliance.

EPA and DHA Are Not Interchangeable

Fish oil contains two main omega-3 fatty acids, EPA and DHA, and most studies bundle them together. But animal research suggests they work through different pathways and have different strengths. In one study using obese rats, both EPA and DHA prevented liver fat from increasing beyond baseline levels, but DHA was more effective at reducing the enzyme responsible for making new fat, shrinking lipid droplets, reversing early fibrotic damage, and lowering fasting insulin. EPA was more effective at reducing a protein involved in glucose metabolism.⁹

A mouse study using a high-fat diet told a slightly different story. EPA was better at lowering liver triglycerides, while DHA was better at reducing liver inflammation and oxidative stress. Neither outperformed the other on fibrosis.¹⁰ These are animal findings and cannot be directly translated to human dosing recommendations, but they hint at why a supplement heavily weighted toward one fatty acid might perform differently than a balanced fish oil. If future clinical trials can tease apart EPA and DHA effects in humans, it could explain some of the inconsistency in the current evidence base.

Metabolic Benefits That Go Beyond the Liver

Fatty liver rarely exists in isolation. Most people with the condition also have elevated triglycerides, insulin resistance, or other features of metabolic syndrome. Even if omega-3’s direct effect on liver fat turns out to be modest, its effects on these surrounding metabolic problems are better established. A meta-analysis of randomized trials found that omega-3 supplementation significantly lowered blood triglycerides and improved insulin resistance (measured by HOMA-IR) and fasting glucose levels in patients with fatty liver disease.¹¹

A review in the World Journal of Gastroenterology noted that omega-3 fatty acids have a broader beneficial impact on cardiometabolic risk factors including blood pressure, blood lipids, and blood vessel function, all of which tend to be abnormal in fatty liver patients and all of which contribute to the cardiovascular disease that is actually the leading cause of death in this population.¹² So while omega-3 may not be a standalone liver treatment, it addresses several of the metabolic problems that make fatty liver dangerous in the first place.

Eating Fish vs. Taking a Capsule

Most of the clinical trial evidence involves fish oil capsules, but there is epidemiological evidence that eating actual fish may matter more. A study of a Mediterranean population found that people in the highest quartile of EPA and DHA intake from food had roughly 40 to 50 percent lower odds of having fatty liver disease compared to those in the lowest quartile. Fatty fish drove most of this association; shellfish and processed or frozen fish showed weaker or no protective effects.¹³

This kind of observational data cannot prove that fish consumption itself prevents fatty liver, because people who eat a lot of fish tend to have other dietary and lifestyle habits that protect the liver too. But it does raise an interesting question: the benefits seen with whole fish consumption in population studies appear stronger and more consistent than those seen with fish oil capsules in trials. One possible explanation is that fish provides a food matrix of protein, selenium, vitamin D, and other nutrients that act together, and isolating the omega-3 component into a capsule captures only part of the benefit. Another is that people who eat fish regularly may be displacing less healthy foods from their diet, which itself reduces liver fat.

What the Evidence Looks Like in Children

Fatty liver disease in children is increasingly common, and parents often ask whether omega-3 supplements might help. The evidence here is mixed at best. A review in Canadian Family Physician concluded that omega-3 is associated with small improvements in liver fat and triglyceride levels in children, but found conflicting results on liver enzyme levels and insulin resistance, and little evidence that fibrosis improves.¹⁴

A randomized controlled trial specifically in children with fatty liver tested omega-3 against placebo for six months. On the primary outcome, which was a meaningful reduction in ALT levels, omega-3 was not superior to placebo. It also showed no significant benefit for reducing fat on ultrasound, improving insulin resistance, or changing BMI. The omega-3 group did have lower AST and GGT levels and higher adiponectin, a hormone linked to metabolic health, but these were secondary outcomes.¹⁵ The Canadian Family Physician review noted that for children who have struggled with diet changes, omega-3 supplementation could play a supporting role alongside the core treatment of diet and exercise, particularly for those with elevated triglycerides.¹⁴

Combining Omega-3 with Exercise

Since diet and exercise are the frontline treatments for fatty liver, it is natural to wonder whether omega-3 and exercise together are better than either alone. The answer from the limited research is surprisingly contradictory. An animal study using overeating-prone rats found that exercise alone lowered liver triglycerides, but adding omega-3 supplementation to exercise actually blunted the benefit, meaning the combination was worse than exercise alone.¹⁶ That is a concerning and counterintuitive finding, though it comes from a single animal model.

In contrast, a human study of young men found that six weeks of high-intensity interval training combined with omega-3 supplementation led to greater improvements in liver enzymes, blood lipids, weight, and body fat than training with placebo.¹⁷ The participants in this trial were young and healthy, not patients with established fatty liver, so the results may not translate directly. The conflicting findings between these studies highlight how little we know about the interaction between omega-3 and exercise in fatty liver specifically. The safest conclusion is that exercise alone has strong evidence for reducing liver fat, and omega-3 should be considered as a potential add-on rather than a reason to skip the workout.

Your Genetics Can Shape the Response

Not everyone responds to omega-3 the same way, and part of that variation may come down to genetics. A common variant in the PNPLA3 gene, known as the I148M mutation, is one of the strongest genetic risk factors for fatty liver disease. A systematic review found moderate evidence that people who carry two copies of this variant benefit less, or not at all, from omega-3 supplementation in terms of reducing liver fat. People without the variant showed moderate benefit.¹⁸

This is a reminder that fatty liver is not one disease with one response profile. The PNPLA3 variant is carried by a significant portion of the population, especially among people of Hispanic descent and those of European ancestry. If you have a strong family history of fatty liver disease and omega-3 supplements seem to do nothing for your liver fat on imaging, your genotype may be part of the explanation. Genetic testing for PNPLA3 is not yet routine in clinical practice, but awareness of this interaction is growing among hepatologists.

The Omega-6 to Omega-3 Balance

One piece of the puzzle that often gets lost in discussions about omega-3 supplements is the role of omega-6 fatty acids. Modern Western diets are heavily tilted toward omega-6 fats, found in vegetable oils, processed foods, and grain-fed animal products. The ratio of omega-6 to omega-3 in a typical Western diet can be 15:1 or higher, compared to the roughly 1:1 to 4:1 ratio that characterized human diets for most of evolutionary history. Animal research has shown that this imbalance directly affects the liver. Mice fed a diet high in omega-6 developed significantly more fat accumulation, more liver cell death, and more of the inflammatory changes associated with fatty liver progression compared to mice fed a diet rich in long-chain omega-3s.¹⁹

This reframes the question somewhat. It is not just whether adding omega-3 helps; it is also whether reducing omega-6 matters. Taking a fish oil capsule while still consuming large amounts of soybean oil, corn oil, and processed snack foods may be working against itself. Some researchers have argued that restoring a healthier omega-6 to omega-3 ratio, rather than simply supplementing omega-3 on top of a bad diet, is the more meaningful intervention for the liver. From a practical standpoint, that means eating more fatty fish while also cooking with oils lower in omega-6 (olive oil, for instance) and cutting back on ultra-processed foods.

Safety Considerations at Higher Doses

Fish oil supplements are widely considered safe, and for most people at typical doses they are. The most common side effects are fishy burps, mild GI discomfort, and occasionally loose stools. But a safety signal worth knowing about has emerged at higher doses. An updated meta-analysis of 35 trials involving over 114,000 people found that omega-3 supplements increased the risk of atrial fibrillation, an irregular heart rhythm, but only in a specific subgroup: patients already at high risk for cardiovascular disease who took high doses of EPA and DHA (above 1,500 mg per day). In that group, the odds of atrial fibrillation increased by about 43 percent relative to controls, though the absolute risk increase was small, under 1 percent. People at lower cardiovascular risk, or those taking lower doses, showed no statistically significant increase in atrial fibrillation risk.²⁰

This matters for fatty liver patients because many of them also have metabolic syndrome, diabetes, or established heart disease, which would place them in that higher-risk category. If you are considering high-dose omega-3 for fatty liver and you already have cardiovascular risk factors, the potential heart rhythm issue is worth discussing with your doctor. At doses in the range of 1,000 to 1,500 mg per day of combined EPA and DHA, the risk does not appear elevated, but the clinical trials for fatty liver have used a wide range of doses without settling on a clear optimum.